


Claims

1. A compound of formula (I):




Compound (I)

that is:


4-(4-(4-(((3*R*,5*R*)-5-((1*H*-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-*N*-(2-hydroxycyclohexyl)benzamide,
or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in the form of a stereoisomer selected from Compounds (Ia) and (Ib):



or a pharmaceutically acceptable salt of any one thereof

3. A compound according to claim 2 which is Compound (Ia):




Compound (Ia)

that is:

4-(4-(4-(((3*R*,5*R*)-5-((1*H*-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-*N*-((1*S*,2*S*)-2-hydroxycyclohexyl)benzamide,
or a pharmaceutically acceptable salt thereof.


4. A compound according to any one of claims 1 to 3 provided as a singular stereoisomer.
5. A compound according to any one of claims 1 to 4 for use as a pharmaceutical.
6. A compound according to any one of claims 1 to 4 for use in the treatment of mycoses or for use in the prevention or treatment of disease associated with mycoses.
7. Use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of mycoses or for the prevention or treatment of disease associated with mycoses.
8. A compound for use or use according to claim 6 or 7 wherein the mycosis is caused by *Aspergillus* spp., such as *Aspergillus fumigatus* or *Aspergillus flavus*, especially *Aspergillus fumigatus*.
9. A compound for use or use according to claim 6 or 7 wherein the mycosis is caused by *Aureobasidium pullulans*, *Rhizopus oryzae*, *Cryptococcus neoformans*, *Chaetomium globosum*, *Penicillium chrysogenum*, *Fusarium graminearum*, *Cladosporium herbarum*, *Trichophyton rubrum* or *Candida* spp. e.g. *Candida albicans*, *Candida glabrata* or *Candida krusei*.
10. A compound for use or use according to claim 6 or 7 wherein the mycosis is an azole resistant mycosis.
11. A compound according to any one of claims 1 to 4 for use as a pharmaceutical in combination with a second or further active ingredient.
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 optionally in combination with one or more pharmaceutically acceptable diluents or carriers.
13. A pharmaceutical composition according to claim 12 which comprises a second or further active ingredient.
14. A compound for use according to claim 11 or a pharmaceutical composition according to claim 13 wherein the second or further active ingredient is selected from anti-fungal agents including azole anti-fungal agents (such as voriconazole, posaconazole, itraconazole or isavuconazole), amphotericin B, an echinocandin (such as caspofungin) and an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (such as lovastatin, pravastatin or fluvastatin).
15. A compound for use according to claim 11 or a pharmaceutical composition according to claim 13 wherein the second or further active ingredient is selected from voriconazole, posaconazole, itraconazole and caspofungin.

16. A compound of formula (3)



5

wherein P represents an amine protective group;
or a salt thereof; or
a compound of formula (4)




10

or a salt thereof.

17. A compound of formula (5)


15



wherein R represents C₁₋₅alkyl;
or a salt thereof.

20

18. A compound of formula (6)



25

or a salt thereof.